Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Separation and Distribution Agreement with Illumina setting agreements for the Spin-Off and the ongoing relationship.
Illumina contributed cash before the Spin-Off to cover 2.5 years of operations (Disposal Funding), which may have to be returned under certain restricted-period transactions.
Tax Matters Agreement governing tax rights, responsibilities and obligations after the Distribution.
Employee Matters Agreement addressing employment, compensation and benefits matters tied to the Spin-Off.
Stockholder and Registration Rights Agreement granting Illumina registration rights and voting arrangements for its shares.
Supply and commercialization agreement under which the Company pays Illumina a royalty on oncology net sales, with royalties suspended while GRAIL is an Illumina affiliate.
Two license agreements under which Illumina pays the Company licensing fees, minimum royalties and running royalties.
Illumina purchased Galleri tests from the Company.
Illumina's 2021 acquisition of GRAIL, in which Illumina issued contingent value rights to GRAIL holders; Illumina retains the CVR obligation after the Spin-Off.
Loading...
